ClinicalTrials.gov
public full text
Public Domain
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are the major factors in sodium and water retention in pulmonary arterial hypertension with right ventricular failure. Natriuretic doses of mineralocorticoid antagonist and aquaretic doses of V2 receptor antagonist will attenuate the sodium and water retention respectively, and be associated with clinical improvement.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A word of caution - potential limitations of pulmonary artery pressure monitoring in detecting congestion caused by right-sided heart failure#472130
- Correlation of Right Atrial Strain With Pulmonary Hypertension, Right Ventricular Function And Outcome In Pediatric Patients#900777
- Prevalence and prognostic significance of pulmonary hypertension in adults with left ventricular diastolic dysfunction#431735
- Right Ventricular and Pulmonary Artery Evaluation by CMR#1074269
- Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.#1010045
Record · ID 827688
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive